Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP388683.RAtepAPrhddjTx3kDSYpH6LyiK53Hw2lnNAEEwoO_Pxig130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP388683.RAtepAPrhddjTx3kDSYpH6LyiK53Hw2lnNAEEwoO_Pxig130_assertion type Assertion NP388683.RAtepAPrhddjTx3kDSYpH6LyiK53Hw2lnNAEEwoO_Pxig130_head.
- NP388683.RAtepAPrhddjTx3kDSYpH6LyiK53Hw2lnNAEEwoO_Pxig130_assertion description "[We correlated the immunolabeling of EZH2 with multiple clinicopathologic features, including Fuhrman nuclear grade, pathologic stage, metastatic status, and clinical outcome in 223 clear cell RCCs (CRCCs) and 21 papillary RCCs, by using tissue microarrays of primary and metastatic cases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP388683.RAtepAPrhddjTx3kDSYpH6LyiK53Hw2lnNAEEwoO_Pxig130_provenance.
- NP388683.RAtepAPrhddjTx3kDSYpH6LyiK53Hw2lnNAEEwoO_Pxig130_assertion evidence source_evidence_literature NP388683.RAtepAPrhddjTx3kDSYpH6LyiK53Hw2lnNAEEwoO_Pxig130_provenance.
- NP388683.RAtepAPrhddjTx3kDSYpH6LyiK53Hw2lnNAEEwoO_Pxig130_assertion SIO_000772 24079759 NP388683.RAtepAPrhddjTx3kDSYpH6LyiK53Hw2lnNAEEwoO_Pxig130_provenance.
- NP388683.RAtepAPrhddjTx3kDSYpH6LyiK53Hw2lnNAEEwoO_Pxig130_assertion wasDerivedFrom befree-20150227 NP388683.RAtepAPrhddjTx3kDSYpH6LyiK53Hw2lnNAEEwoO_Pxig130_provenance.
- NP388683.RAtepAPrhddjTx3kDSYpH6LyiK53Hw2lnNAEEwoO_Pxig130_assertion wasGeneratedBy ECO_0000203 NP388683.RAtepAPrhddjTx3kDSYpH6LyiK53Hw2lnNAEEwoO_Pxig130_provenance.